Key facts for Q9997
- Billing unit
- 1 MG
- Ustekinumab-ttwe iv inj 1 mg
- ASP payment limit
- $8.591
- October 2026; +0.5% vs July 2026
- Practitioner MUE
- 520
- MAI 3
- NCCI exposure
- no PTP pairs
- Coverage articles
- 0
- none list this code
TL;DR
HCPCS Q9997 is the Level II code for Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $8.591 per billing unit, up 0.5% from July 2026. The practitioner MUE allows up to 520 units per date of service (MAI 3), so a full 520-unit day is $4,467.32 at the current limit. Under OPPS it carries status indicator K in APC 0914. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names ustekinumab: Q9998 (biosimilar ustekinumab-aekn (Selarsdi) from Nupathe Inc); Q9999 (biosimilar ustekinumab-aauz (Otulfi) from Fresenius Kabi USA, LLC); Q5138 (biosimilar ustekinumab-auub (Wezlana) from Optum Health Solutions Ireland Limited); Q5100 (biosimilar ustekinumab-kfce (Yesintek) from Biocon Biologics Inc); Q5099 (biosimilar ustekinumab-stba (Steqeyma)); Q5098 (biosimilar ustekinumab-srlf (Imuldosa) from Accord BioPharma, Inc). The ASP crosswalk maps 2 NDCs to it, sold as Pyzchiva, Ustekinumab-TTWE by Sandoz Inc., Quallent Pharmaceuticals. No current Billing and Coding Article lists Q9997, so coverage follows the FDA label, compendia and any applicable NCD.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for Q9997 at $8.591 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $8.552 in July 2026. Beneficiary coinsurance is 20%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $8.591 | 1 MG | 20% |
| July 2026 | $8.552 | 1 MG | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk maps 2 NDCs from 2 labelers to Q9997. Report the NDC in the claim's drug segment and bill the number of Q9997 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 61314-0654-94 | Pyzchiva | Sandoz Inc. | 26 × 1 | 130 |
| 82009-0163-94 | Ustekinumab-TTWE | Quallent Pharmaceuticals | 26 × 1 | 130 |
Medically Unlikely Edits (MUE)
CMS publishes 3 MUE values for Q9997. For practitioners the limit is 520 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.
| Setting | MUE (units/DOS) | MAI | CMS rationale |
|---|---|---|---|
| Practitioner services | 520 | 3 Date of Service Edit: Clinical | Prescribing Information |
| Facility outpatient hospital | 520 | 3 Date of Service Edit: Clinical | Prescribing Information |
| DME supplier | 520 | 3 Date of Service Edit: Clinical | Prescribing Information |
MUE for Q9997 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
No active practitioner PTP pair lists Q9997 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.
The counts above are exposure, not answers for a specific claim. Check Q9997 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
Q9997 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
No current Billing and Coding Article lists Q9997 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, Q9997 carries status indicator K and is assigned to APC 0914, with a published national unadjusted payment of $8.591. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), Q9997 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $8.59 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.
Common denials for Q9997 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for Q9997
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS Q9997
What does HCPCS code Q9997 describe?
Q9997 is defined by CMS as "Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.
Is Q9997 a CPT code?
No. Q9997 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as ustekinumab-ttwe (Pyzchiva); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q9997 reports the drug itself in 1 mg units, and the administration is billed on its own line.
What is the Medicare reimbursement for Q9997 in October 2026?
The ASP-based payment limit is $8.591 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $8.552. Commercial payers use their own fee schedules.
How many units of Q9997 can be billed per day?
The practitioner Medically Unlikely Edit is 520 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.
Which NDCs map to Q9997?
The October 2026 ASP crosswalk lists 2 NDCs from 2 labelers: Pyzchiva (Sandoz Inc.); Ustekinumab-TTWE (Quallent Pharmaceuticals). For example NDC 61314-0654-94 (package size 26) equals 130 billing units of Q9997.
Does Q9997 have NCCI bundling edits?
No active practitioner PTP pairs list Q9997 as a column-1 or column-2 code in the v323r0 release.
Q9997 vs Q9998: what is the difference?
Both are HCPCS Level II codes whose descriptor names ustekinumab. What sets Q9998 apart: biosimilar ustekinumab-aekn (Selarsdi) from Nupathe Inc. Q9997 is billed per 1 mg, limit $8.591, MUE 520; Q9998 is billed per 1 mg, limit $10.48, MUE 520. Report the code whose descriptor matches the product and setting in the record.
Q9997 vs Q9999: what is the difference?
Both are HCPCS Level II codes whose descriptor names ustekinumab. What sets Q9999 apart: biosimilar ustekinumab-aauz (Otulfi) from Fresenius Kabi USA, LLC. Q9997 is billed per 1 mg, limit $8.591, MUE 520; Q9999 is billed per 1 mg, limit $13.246, MUE 520. Report the code whose descriptor matches the product and setting in the record.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.